I’ve been following Achillion Pharmaceuticals (ACHN) for quite some time, but became more interested after the company reported positive results of its factor D inhibitor ACH-4471 in two rare diseases – PNH and C3G.
The problem with PNH is that the results aren’t good enough for the drug to effectively compete with a heavily entrenched drug – Alexion’s (ALXN) Soliris. The data of ACH-4471 in combination with Soliris have produced promising results, but there are questions there about pricing of the combination since Soliris is one of the most expensive drugs